Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 15/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29638127 | 0.84 | MAOB (1.00) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL1379497 | 0.84 | MAOB (1.00) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL7021392 | 0.82 | GSK3B (0.58) | MAOBAPPGSK3BBACE1IDO1 | |
| SCHEMBL1578152 | 0.82 | MAOB (1.00) | MAOBGAAMAPTMAOARAB9A | |
| Hydrochloric Acid SCHEMBL2197705 | 0.82 | MAOB (1.00) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL5096562 | 0.81 | MAOB (0.50) | MAOBGSK3BBACE1IDO1 | |
| SCHEMBL28030449 | 0.81 | APP (0.55) | MAOBMAOAAPPGSK3BBACE1 | |
| SCHEMBL810747 | 0.80 | MAOB (0.67) | MAOBMAPTMAOAAPPIDO1 | |
| SCHEMBL26127859 | 0.80 | MAOB (0.59) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL31542030 | 0.79 | MAOB (0.80) | MAOBGAAMAPTMAOARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20060258723-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PFIZER INC | 2006-11-16 | — | — | US | disclosed |
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | MAOB 4263/4885GAA 1367/4885MAPT 1786/4885 |
| US-20060258723-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARG, PPARA, PPARD | MAOB 4396/4885GAA 1398/4885MAPT 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.